- A piperazine-containing aminopyrimidine derivative and its application
-
The present invention discloses a piperazine-containing aminopyrimidine derivative having a general formula I. structure, which belongs to kinase CDK4, CDK6 and / or CDK9 inhibitors, can be more widely used in the treatment of a variety of cancers, has gr
- -
-
Paragraph 0124; 0137-0139
(2022/01/12)
-
- A 2-aminopyrimidine heterocyclic compound and its applications
-
The present invention discloses a 2-aminopyrimidine heterocyclic compound having a general formula I structure and its applications, which are kinase CDK4, CDK6 and / or CDK9 inhibitors, can be more widely used in the treatment of a variety of cancers, ha
- -
-
-
- A pyrimidine compound and its application
-
The present invention discloses a pyrimidine amine compound having a general formula I structure and its applications, the class of compounds belongs to the kinase CDK4, CDK6 and / or CDK9 inhibitors, can be more widely used in the treatment of a variety
- -
-
Paragraph 0084; 0091-0092; 0105-0107
(2022/01/12)
-
- Hydrogen Evolution from Telescoped Miyaura Borylation and Suzuki Couplings Utilizing Diboron Reagents: Process Safety and Hazard Considerations
-
The hazard assessment of a telescoped Miyaura borylation and Suzuki coupling reaction employing bis(pinacolato)diboron (BisPin), used in the developmental synthesis of an intermediate for abemaciclib, led to the observation of hydrogen being generated. Quantitative headspace GC and solution 11B NMR were used to show that the rapid decomposition of the excess BisPin from the borylation under the aqueous basic conditions of the Suzuki reaction was responsible for H2 generation. The moles of H2 observed were found equal to the BisPin excess, which is rationalized by mass balance and a stoichiometric reaction. The possible generation of the stoichiometric levels of H2 should be considered in hazard assessments of this class of reaction. Kinetic and process modeling was used to minimize the risk upon scale-up, and results for commercial manufacturing batches are presented, which showed good agreement with the lab scale data. Furthermore, the hydrogen evolution potentials of other common borylating agents including bisboronic acid (BBA) and pinacol borane were demonstrated.
- Borkar, Indrakant,Brewer, Alison Campbell,Buser, Jonas Y.,Campos, Odilon,Fleming, Jeffrey,Forst, Mindy B.,Hansen, Caoimhe,Humenik, Ashley,Jeffery, Stephen,Kokitkar, Prashant B.,Kolis, Stanley P.,Lambertus, Gordon R.,Martinelli, Joseph R.,McCartan, Ciaran,Merritt, Jeremy M.,Moursy, Hossam,Murphy, Donal,Murray, Michael M.,O'Donnell, Kevin,O'Sullivan, Rita,Richardson, Gary A.,Xia, Han
-
-
- DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
-
The present application provides bifunctional compounds, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 4 (CDK4) and/or cyclin-dependent kinase 6 (CDK6). The present application also relates to methods for the targeted degradation of CDK4 and/or CDK6 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK4 and/or
- -
-
Page/Page column 96-97
(2020/02/16)
-
- Novel synthesis method of Abemaciclib mesylate
-
The invention discloses a synthesis method of Abemaciclib mesylate. The method comprises steps as follows: (1), a compound 9 in the description is subjected to a reaction with a compound 5 in the description under the action of strong base, and a compound
- -
-
-
- AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY
-
An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.
- -
-
Paragraph 0315-0316
(2019/06/07)
-
- CRYSTALLINE POLYMORPHS OF ABEMACICLIB
-
The present disclosure provides novel polymorphs of abemaciclib, solid dispersions of abemaciclib with pharmaceutical excipients, and processes for the preparation thereof. The disclosure further provides methods for preparing crystalline abemaciclib form I, amorphous abemaciclib, and methods for synthesizing abemaciclib.
- -
-
-
- NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF
-
The present invention discloses a nitrogen-containing fused heterocyclic compound, as well as a preparation method, intermediate, composition and application thereof. The nitrogen-containing fused heterocyclic compound of the present invention as represented by formula (I), as well as the pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, metabolite or drug precursor thereof, exhibit a high selectivity and a high inhibitory activity with respect to CDK4 and CDK6 at a molecular level, an excellent inhibitory activity with respect to breast cancer cells at a cellular level, and significant inhibition of tumor cell proliferation associated with cyclin-dependent kinase activity at an animal level. The invention also exhibits a good stability with respect to human or mouse liver microsomes without significant inhibition of metabolic enzymes, good in vivo absorption in mice and rats, a high bioavailability and good druggability.
- -
-
Paragraph 0205; 0207
(2019/01/25)
-
- Application of benzimidazole derivative used as inhibitor of cyclin dependent kinase 4/6
-
The invention relates to an application of a benzimidazole derivative used as an inhibitor of cyclin dependent kinase 4/6. The benzimidazole derivative provided by the invention has a structure as shown in a formula (I) which is described in the specification. In the formula (I), substituents are described in the description.
- -
-
-
- A novel benzimidazole - pyrimidinamine derivatives, and use thereof
-
The invention provides a deuterated benzimidazole-pyrilamine derivative which is a compound shown in formula (I) shown in the specification or a pharmaceutically acceptable salt, a monocrystal substance or a polymorphic substance of the compound as well as an application of the derivative to preparation of drugs for treating cancer, and further provides pharmaceutical composition containing the compound. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 refer to hydrogen or deuterium independently, and at least one deuterium is contained in total. The deuterated benzimidazole-pyrilamine derivative mesylate prolongs half-life periods of the drugs, prolongs the retention time of the drugs in human bodies and increases concentration of the drugs in blood, so that the better curative effect can be realized.
- -
-
Paragraph 0064; 0065; 0066in
(2018/03/26)
-
- Substituted benzimidazole derivatives
-
The invention belongs to the field of pharmaceutical chemistry, particularly relates to substituted benzimidazole derivatives as well as a preparation method and pharmaceutical composition thereof and further relates to an application of the substituted b
- -
-
-
- Deuterium-modified Abemaciclib derivative
-
The invention belongs to the field of medicinal chemistry and specifically relates to a deuterium-modified Abemaciclib derivative, a preparation method of the derivative, a pharmaceutical composition containing the deuterium-modified Abemaciclib derivative, and application of the deuterium-modified Abemaciclib derivative and the pharmaceutical composition in the preparation of a medicine for treating cell proliferative diseases. In comparison with Abemaciclib, some compounds of the invention (especially compounds in the embodiment) have more excellent pharmacokinetic properties. It is expected that clinical dosage will be reduced. Thus, treatment cost is reduced so as to benefit more patients.
- -
-
Paragraph 0101; 0102; 0103; 0104; 0105; 0106; 0132-0137
(2017/08/02)
-
- DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
-
The present application provides bifunctional compounds of Formula (I), or Targeting Ligand, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 4 (CDK4) and/or cyclin-dependent kinase 6 (CDK6). The present application also relates to methods for the targeted degradation of CDK4 and/or CDK6 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK4 and/or CDK6 which can be utilized in the treatment of disorders modulated by CDK4 and/or CDK6.
- -
-
Page/Page column 96
(2017/11/15)
-
- COMBINATION THERAPY FOR CANCER
-
The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H- benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.
- -
-
-
- A synthesis of abemaciclib utilizing a Leuckart-Wallach reaction
-
A concise total synthesis of CDK 4/6 inhibitor abemaciclib is described. The synthesis uses a Suzuki coupling, followed by a Hartwig-Buchwald amination to join three of the four subunits. The final step is a reductive amination utilizing Leuckart-Wallach conditions. Key to the Leuckart-Wallach reaction was the addition of trimethyl orthoformate to remove water formed during the reaction, allowing the reaction to go to completion.
- Frederick, Michael O.,Kjell, Douglas P.
-
p. 949 - 951
(2015/02/05)
-
- PROTEIN KINASE INHIBITORS
-
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
- -
-
Page/Page column 11
(2010/07/04)
-
